WO2010133374A3 - Therapeutic composition comprising microspheres - Google Patents

Therapeutic composition comprising microspheres Download PDF

Info

Publication number
WO2010133374A3
WO2010133374A3 PCT/EP2010/003120 EP2010003120W WO2010133374A3 WO 2010133374 A3 WO2010133374 A3 WO 2010133374A3 EP 2010003120 W EP2010003120 W EP 2010003120W WO 2010133374 A3 WO2010133374 A3 WO 2010133374A3
Authority
WO
WIPO (PCT)
Prior art keywords
microspheres
therapeutic composition
active ingredient
treating
injection
Prior art date
Application number
PCT/EP2010/003120
Other languages
French (fr)
Other versions
WO2010133374A2 (en
Inventor
Ipsita Roy
Original Assignee
University Of Westminster
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Westminster filed Critical University Of Westminster
Publication of WO2010133374A2 publication Critical patent/WO2010133374A2/en
Publication of WO2010133374A3 publication Critical patent/WO2010133374A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

An injectable microsphere comprising an active ingredient for treating an ocular disorder for example wet macular degeneration and which provides controlled release of the active ingredient over a prolonged period whereby the frequency of injection as compared to known treatments is reduced.
PCT/EP2010/003120 2009-05-20 2010-05-20 Therapeutic composition comprising microspheres WO2010133374A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0908685.1 2009-05-20
GB0908685A GB2470378A (en) 2009-05-20 2009-05-20 A controlled release composition for intraocular delivery of a therapeutic agent

Publications (2)

Publication Number Publication Date
WO2010133374A2 WO2010133374A2 (en) 2010-11-25
WO2010133374A3 true WO2010133374A3 (en) 2011-01-13

Family

ID=40862699

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/003120 WO2010133374A2 (en) 2009-05-20 2010-05-20 Therapeutic composition comprising microspheres

Country Status (2)

Country Link
GB (1) GB2470378A (en)
WO (1) WO2010133374A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3121353B1 (en) * 2021-03-31 2024-03-22 Chanel Parfums Beaute Cosmetic composition comprising at least one polyhydroxyalkanoate

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0172422A2 (en) * 1984-08-01 1986-02-26 Hoechst Aktiengesellschaft Microcapsules of regulatory peptides with controlled release, their preparation and injectable formulations
EP1867348A2 (en) * 1999-03-25 2007-12-19 Metabolix, Inc. Medical devices and applications of polyhydroxyalkanoate polymers
US20080014144A1 (en) * 2004-07-01 2008-01-17 Yale University Methods of Treatment with Drug Loaded Polymeric Materials

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ224549A (en) * 1987-05-29 1990-04-26 Ici Australia Operations Controlled release polymer microspheres containing at least one active agent
FR2693905B1 (en) * 1992-07-27 1994-09-02 Rhone Merieux Process for the preparation of microspheres for the sustained release of the hormone LHRH and its analogs, microspheres and formulations obtained.
US6447796B1 (en) * 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US20050025809A1 (en) * 2003-07-08 2005-02-03 Tepha, Inc. Poly-4-hydroxybutyrate matrices for sustained drug delivery
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
WO2007130134A2 (en) * 2005-12-02 2007-11-15 (Osi) Eyetech, Inc. Controlled release microparticles
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
WO2008157614A2 (en) * 2007-06-21 2008-12-24 Yale University Sustained intraocular delivery of drugs from biodegradable polymeric microparticles

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0172422A2 (en) * 1984-08-01 1986-02-26 Hoechst Aktiengesellschaft Microcapsules of regulatory peptides with controlled release, their preparation and injectable formulations
EP1867348A2 (en) * 1999-03-25 2007-12-19 Metabolix, Inc. Medical devices and applications of polyhydroxyalkanoate polymers
US20080014144A1 (en) * 2004-07-01 2008-01-17 Yale University Methods of Treatment with Drug Loaded Polymeric Materials

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
YUJI YAMAMOTO ET AL: "An experimental study on the releasing rate of poly(3-hydroxybutyrate) microspheres", DRUG DELIVERY SYSTEM, NIHON D D S GAKKAI, JAPAN, vol. 7, no. 5, 1 September 1992 (1992-09-01), pages 367 - 371, XP008127817, ISSN: 0913-5006 *
YUJI YAMAMOTO ET AL: "An experimental study on the releasing rate of Poly(3-hydroxybutyrate) microspheres-II", DRUG DELIVERY SYSTEM, NIHON D D S GAKKAI, JAPAN, vol. 8, no. 2, 1 March 1993 (1993-03-01), pages 131 - 136, XP008127818, ISSN: 0913-5006 *

Also Published As

Publication number Publication date
GB0908685D0 (en) 2009-07-01
WO2010133374A2 (en) 2010-11-25
GB2470378A (en) 2010-11-24

Similar Documents

Publication Publication Date Title
WO2011107750A3 (en) Delayed prolonged drug delivery
IL252775A0 (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
WO2011107749A3 (en) Pulsatile drug release
WO2012064973A3 (en) Heterocyclic compounds and uses thereof
WO2013012915A9 (en) Heterocyclic compounds and uses thereof
GB2491328A (en) Immediate/delayed drug delivery
WO2012158991A3 (en) Controlled application of cross-linking agent
WO2012063237A3 (en) Buffered ophthalmic compositions and methods of use thereof
EP2750660A4 (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
WO2011084366A3 (en) Compositions and drug delivery systems for intraocular delivery of sirna molecules, their use for treating conditions
WO2011139794A3 (en) A composition for skin sanitization and protection and method of its use
WO2012080497A3 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
WO2011049327A3 (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
GEP20196969B (en) New therapeutical composition containing apomorphine as active ingredient
WO2011085216A3 (en) Use of faah inhibitors for treating parkinson's disease and restless legs syndrome
WO2011129765A9 (en) Synergistic interaction of at least one vitamin e component and tyrosinase inhibitors for dermatological applications
WO2012097272A8 (en) Stable hydrogel compositions including additives
EP2575842A4 (en) A composition comprising the extract of physalis alkekengi var. francheti hort as an active ingredient for preventing and treating inflammatory diseases
EP2301561A4 (en) Pharmaceutical composition for treatment of dry eye and/or corneal/conjunctival disorders
WO2012106058A3 (en) Animal treatments
WO2013006558A3 (en) Compositions and methods for treating skeletal myopathy
HK1141451A1 (en) Composition of biocompatible microparticles of alginic acid for the controlled release of active ingredients by intravenous administration
GB0916573D0 (en) Composition for treatment of wounds and burns comprising bee-venom as active
WO2013059233A3 (en) Thermoresponsive compositions for dermatological use and methods thereof
WO2013028904A3 (en) Dermal filler compositions including antioxidants

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10720275

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10720275

Country of ref document: EP

Kind code of ref document: A2